European Society of Cardiology/European Atherosclerosis Society 2016 and 2019 risk-based low-density lipoprotein cholesterol goal attainment among patients stabilized on lipid-lowering regimens summarized by level of risk and statin regimen. (A) The overall group summarized by level of risk and statin regimen (B) The Primary prevention group summarized by level of risk and statin regimen. (C) The established atherosclerotic cardiovascular disease group^b summarized by level of risk and statin regimen. ^aGoal attainment for low risk is the same for 2016 and 2019 (<3.0 mmol/L) so only one bar is displayed. ^bIndividuals with established atherosclerotic cardiovascular disease are, by definition, very high cardiovascular risk. N is the number of patients in the category with non-missing low-density lipoprotein cholesterol goal data. Patients enrolled as secondary prevention whose first atherosclerotic cardiovascular disease event occurred after the date low-density lipoprotein cholesterol levels were stabilized are included in the primary prevention group. Among patients enrolled as secondary prevention, 142 had their first cardiovascular event recorded after their most recent low-density lipoprotein cholesterol measurement, hence they were analysed as primary prevention patients for outcomes assessed at low-density lipoprotein cholesterol measurement, such as goal attainment. For outcomes assessed at enrolment, these 142 patients were analysed as secondary prevention. Definitions of lipid-lowering therapy categories are described in Supplementary material online, Table S2. LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.